Abstract
Imaging techniques targeting tumor angiogenesis have been investigated for past decade. Of these, the radiolabeled Arg-Gly- Asp (RGD) peptide has been focused because it has high affinity and selectivity for integrin alpha(v)beta3. Integrin alpha(v)beta3 is expressed on the plasma membrane in an active status in which it binds its ligands and transduce signals when exposed activating external stimuli of tumor angiogenesis such as vascular endothelial growth factor (VEGF). Many linear or cyclic RGD peptides were developed for positron emission tomography (PET). In this review, we focused on currently developed RGD peptides as PET probes for non-invasive detection of integrin alpha(v)beta3 expression.
Keywords: Integrin, integrin alpha(v)beta3, angiogenesis, VEGF, PET, positron emission tomography, PET/CT, RGD, radiolabeled-RGD, RGD peptide
Current Medicinal Chemistry
Title:Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Volume: 19 Issue: 20
Author(s): U. Tateishi, T. Oka and T. Inoue
Affiliation:
Keywords: Integrin, integrin alpha(v)beta3, angiogenesis, VEGF, PET, positron emission tomography, PET/CT, RGD, radiolabeled-RGD, RGD peptide
Abstract: Imaging techniques targeting tumor angiogenesis have been investigated for past decade. Of these, the radiolabeled Arg-Gly- Asp (RGD) peptide has been focused because it has high affinity and selectivity for integrin alpha(v)beta3. Integrin alpha(v)beta3 is expressed on the plasma membrane in an active status in which it binds its ligands and transduce signals when exposed activating external stimuli of tumor angiogenesis such as vascular endothelial growth factor (VEGF). Many linear or cyclic RGD peptides were developed for positron emission tomography (PET). In this review, we focused on currently developed RGD peptides as PET probes for non-invasive detection of integrin alpha(v)beta3 expression.
Export Options
About this article
Cite this article as:
Tateishi U., Oka T. and Inoue T., Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers, Current Medicinal Chemistry 2012; 19 (20) . https://dx.doi.org/10.2174/092986712801215937
DOI https://dx.doi.org/10.2174/092986712801215937 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Current Cancer Drug Targets Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Dual-Targeted Molecular Probes for Cancer Imaging
Current Pharmaceutical Biotechnology Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Protein-Modified Magnetic Nanoparticles for Biomedical Applications
Current Organic Chemistry Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry